CareDx (CDNA) vs Celcuity (CELC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
CareDx (CDNA) has outperformed Celcuity (CELC) over the past year, gaining 329.7% versus a gain of 33.7%. Over five years, CELC leads with a +261.4% price change compared with -11.2% for CDNA. CareDx is the larger company by market cap ($3.26 billion vs $3.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | CELC |
|---|---|---|
| Share price | $63.04 | $65.78 |
| Market cap | $3.26B | $3.22B |
| 1-day change | -1.18% | -7.68% |
| YTD return | +234.61% | -34.05% |
| 1-year return | +329.72% | +33.66% |
| 5-year return | -11.21% | +261.43% |
| P/E ratio (TTM) | 30.31 | — |
| Forward P/E | 48.87 | — |
| EPS (TTM) | $2.08 | $-4.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.51 | $151.02 |
| 52-week low | $13.95 | $45.03 |
| Distance from 52-week high | -13.06% | -56.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -6.68% | +138.54% |
| Average volume | 1.28M | 1.18M |
| Shares outstanding | 51.73M | 48.93M |
| Employees | 761 | 155 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed CELC by 296.1 percentage points over the past year.
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
CDNA vs CELC FAQ
Which is bigger, CareDx or Celcuity?
CareDx (CDNA) is larger, with a market capitalization of $3.26B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CDNA or CELC?
CDNA returned +329.72% over the past 12 months, compared with +33.66% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are CareDx and Celcuity in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.